BCL2 and leukemia: Here, we demonstrate that combined inhibition of Bcl-2 by venetoclax and activation of PPARα by chiglitazar has synergistic anti-leukemia activity against LSC-like cell lines (KG-1α and Kasumi-1) and CD34+ primary AML cells while sparing normal cells in vitro.